Skip to main content
  • Overview
    • News
    • Events & Presentations
      • Events
      • Presentations
    • IRA Commentary
      • Halozyme Statement on IRA IPAY 2028
      • Halozyme Letter to CMS on IRA IPAY 2028
      • Comparison Medicare Expenditure for SC versus IV Drugs
      • Patient Experience: SC Treatment
    • Royalty Duration
      • Royalty Duration
      • Financial Guidance
    • Stock Info
      • Stock Information
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Leadership Team
      • Board of Directors
      • Commitment to ESG
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact Us
Skip to main content
Halozyme Therapeutics

IRA Commentary

  • Overview
    • News
    • Events & Presentations
      • Events
      • Presentations
    • IRA Commentary
      • Halozyme Statement on IRA IPAY 2028
      • Halozyme Letter to CMS on IRA IPAY 2028
      • Comparison Medicare Expenditure for SC versus IV Drugs
      • Patient Experience: SC Treatment
    • Royalty Duration
      • Royalty Duration
      • Financial Guidance
    • Stock Info
      • Stock Information
      • Stock Chart
      • Historical Stock Quote
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Leadership Team
      • Board of Directors
      • Commitment to ESG
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact Us

Contact Us

Tram Bui

Vice President, Investor Relations & Corporate Communications

609-359-3016
tbui@halozyme.com
media@halozyme.com
ir@halozyme.com

Quick Links

  • SEC Filings
  • Investor FAQs
  • Resources

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Halozyme Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Halozyme Therapeutics to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*
Unsubscribe

Email Alert Sign Up Confirmation

Halozyme Therapeutics Logo
  • Privacy Policy
  • Cookies Policy
© Q4 Inc. - All rights reserved
Powered By Q4 Inc. 5.168.1.2 (opens in new window)